Oscar Health’s (OSCR) recent plunge shows what happens when markets confuse headlines with reality. Investors dumped shares after Centene Corp. (CNC) warned its ACA members are sicker than expected, blowing a $1.8 billion hole in its risk-adjustment flows. The fear? That every ACA insurer faces the same hidden cost creep. 

But here’s the truth: Oscar never had any Centene partnership to lose. Its only ‘hit’ is the quiet exit from a tiny Cigna co-brand plan, just 1% of revenue, now being replaced by faster-growing direct sign-ups and ICHRA. 

Yes, Oscar is 100% ACA-exposed, so its entire $11 billion book is vulnerable if the pool worsens. But so far, its MLR is trending better than peers, its capital surplus is solid, and its care navigation flywheel keeps members healthier than average. If that holds, this selloff is pure fear pricing, an asymmetric opportunity for patient investors willing to watch how the next few risk-adjustment updates play out.

Context: The Centene “Black Swan” and Its Sector-Wide Reverberations

First, the core issue. Centene’s bombshell announcement in April 2025 warned that its ACA Marketplace plans were experiencing substantially higher morbidity than expected. The upshot: its members were sicker, risk-adjustment flows would swing dramatically negative, and the company would see a multi-billion-dollar revenue hit, erasing profit guidance for the year.

This matters because of the ACA’s risk-adjustment system: every individual and small-group insurer must participate in this “zero-sum” mechanism that redistributes money from plans with healthier-than-average members to those with sicker ones. When a big player like Centene, which operates at massive scale across Medicaid and ACA exchanges, misreads its risk pool, it doesn’t just hurt its own results, it signals a possible pool-wide repricing of average risk. And if the average risk gets worse, everyone must adjust pricing assumptions, reserves, and capital requirements.

So, even though Oscar never had a Centene partnership (despite early headlines conflating the two), the fear is not about lost business. It’s about whether Oscar’s own 2 million ACA members will surprise the company with the same cost creep.

Is Oscar’s 20% Selloff Really Justified?

Oscar Health’s recent 20% plunge erased about $1.5 billion in market value, driven by panic that Centene’s $1.8 billion risk-adjustment shock will spill across the entire ACA sector. It’s fair to worry, Oscar is 100% tied to the ACA Marketplace, so every dollar of its ~$11.2 billion 2025 revenue is exposed if its members prove sicker than forecast. 

But when you unpack the numbers, the magnitude of the drop looks disconnected from Oscar’s real downside. At worst, if its MLR spikes 3–5 points higher, mirroring Centene’s implied pool,  that could add $330–550 million in unexpected claims costs, fully wiping out Oscar’s projected $250 million operating profit for 2025 and pushing it slightly negative. That’s painful for a company that just turned GAAP-profitable for the first time, but it’s hardly a balance-sheet killer: Oscar still has over $1 billion in statutory capital, ~$774 million in excess risk-based capital (RBC), and heavy quota-share reinsurance to cap extreme claim swings.

What the market is missing is Oscar’s unique structural buffer. Unlike Centene, which operates huge Medicaid books with higher morbidity and state-level payment complexities, Oscar’s member pool has historically been healthier than average, hence why it’s been a net payer into the ACA risk-adjustment pool (over $1 billion last year alone). 

If the broader pool does get sicker, Oscar could actually pay out less, partially offsetting higher claims. So far, there’s no evidence Oscar’s pool is deteriorating at Centene’s pace: its Q1 2025 MLR held steady at ~75%, and management reaffirmed full-year guidance even after Centene’s bombshell. Add in a fast-growing ICHRA wedge and strong retention on direct ACA sign-ups, generally lower-risk populations, and the picture looks more stable than the headlines suggest.

The upshot? A worst-case scenario might wipe out a year or two of earnings, but it doesn’t threaten Oscar’s solvency or growth runway. The market priced Oscar as if it will mirror Centene’s miss, yet its early trends and structural cushions show otherwise. If the next two quarters confirm the pool stays healthier-than-average, today’s fear could look like classic mispricing, an asymmetric bet for investors who see past the noise.

Oscar’s Business Mix: What Actually Drives Exposure?

Understanding this risk starts with Oscar’s business model. Oscar today is, by design, a focused ACA insurer:

• 100% of its in-force membership (after exiting its tiny Medicare Advantage line and winding down small-group co-branded PPOs with Cigna) is now concentrated in the individual ACA Marketplace, including a fast-growing ICHRA wedge.
  
• As of Q1 2025, Oscar had about 2.04 million members, up from ~1.04 million at the end of 2023. This makes it one of the fastest-growing ACA insurers by membership base.

This scale matters because ACA risk-adjustment flows touch nearly every dollar of premium Oscar earns. Big commercial group plans or long-tail Medicaid contracts don’t diffuse the company’s exposure. This single-line focus can be both a strength and a vulnerability: the unit economics are easier to manage when you have one product to price well, but the margin for error is thinner if your assumptions are off.

How Risk-Adjustment Works: The Transfer Mechanism

To see why Centene’s warning set off alarm bells, you need to appreciate the zero-sum math. Each year, ACA insurers submit detailed member health data that drives their risk-adjustment payments.

• If your pool is healthier than average, you pay into the system.
  
• If you have sicker members than the statewide benchmark, you receive payments.
  

Oscar’s track record shows that its member base has historically been healthier than average, making it a consistent net payer into the pool. In 2023, Oscar paid over $1 billion in risk-adjustment outflows, more than 20% of its gross premiums. In Q1 2025, the company booked a $31 million adverse reserve adjustment for risk-adjustment, showing that even as the sector gets sicker, the shift isn’t yet swinging dramatically in Oscar’s favor.

MLR Trends: Early Signs of Stability

If Oscar were seeing the same kind of morbidity spike that Centene is, you’d expect to see that show up in the company’s MLR. This is the portion of premiums spent on claims, the key real-time signal of whether costs are rising faster than expected.

So far, Oscar’s trend remains comparatively healthy:

• 2021 MLR: ~88–89%
  
• 2022 MLR: ~85%
  
• 2023 MLR: ~82%
  
• Q1 2025 MLR: ~75.4% (vs. 74.2% Q1 2024)
  

Management still guides for a full-year MLR in the 80–82% range, well below the sector average for ACA plans, which sits closer to 84–85% for the same period. The delta may seem small, but a few points can swing profitability massively.

So, does this guarantee Oscar won’t get blindsided later? Not necessarily. Risk-adjustment true-ups don’t finalize until well after the plan year ends. But the early sign is that Oscar’s member base, thanks to its focus on care navigation, virtual care, and digital engagement, is not yet mirroring Centene’s spike.

Why the Cigna Exit Doesn’t Really Matter

Some bearish commentary has mistakenly conflated Centene’s massive ACA guidance cut with Oscar’s decision to unwind its tiny Cigna co-branded small-group plan. Here’s the reality:

• At its peak, the Cigna+Oscar plan generated ~$229 million in premiums, about 4–5% of Oscar’s top line in 2023.
  
• By 2025, the run-rate is closer to ~$140 million, or about 1% of projected revenue.
  
• Oscar is pivoting its small-group focus into ICHRA and direct ACA sign-ups, a strategy with higher margin potential and lower dependency on external partners.

This means the Cigna unwind isn’t a structural hole in the business. If anything, it trims complexity and tightens capital reserve needs by offloading a low-margin, reinsured slice of business.

Key Catalysts to Watch

To gauge whether the panic is justified or the overreaction becomes an opportunity, investors should track three variables:

1. Q2–Q3 Risk-Adjustment Updates: These will reveal whether Oscar’s risk pool is trending towards Centene’s sicker reality or holding its healthier profile.
   
2. 2025 ACA Subsidy Extension: If Congress fails to renew enhanced subsidies, enrollment could drop and risk pools could deteriorate further. A real structural headwind.
   
3. ICHRA Expansion Pace: How quickly Oscar replaces lost small-group lives with stickier, employer-sponsored individuals will signal whether its revenue base remains resilient.
   

Bottom Line: Is the Selloff Overdone?

Here’s the takeaway: Oscar’s single-line ACA focus does make it exposed to the same macro forces that blindsided Centene. But its healthy MLR trend, well-structured reinsurance, strong statutory capital, and smart ICHRA pivot all provide meaningful defenses that many larger, legacy players can’t replicate.

Yes, the risk is real, a sector-wide morbidity shock can erase thin margins fast. But so far, Oscar’s numbers show the risk-adjustment headwind has not yet hit with the same force. The 20% drawdown likely reflects blanket fear rather than company-specific deterioration.

For investors with a medium-term horizon, that mismatch creates an asymmetric setup: the market prices Oscar like it’s another Centene when it may be better positioned to ride out the ACA volatility with less damage. If risk-adjustment trends confirm that Oscar’s pool stays healthier, the path to a healthy rerating could be clearer than the panic suggests.